FierceBiotech14h
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
lupus.bmj14h
Association of race and ethnicity with mortality in adults with SLE: a systematic literature review and meta-analysis
Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...
lupus.bmj7h
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
BMJ12h
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight ... Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological ...